Not Yet Recruiting EARLY_PHASE1 INTERVENTIONAL 1-arm
NCT07085195
A Clinical Study of the Safety and Efficacy of Chemogenetics Therapy in the Treatment of Parkinson's Disease
Sponsor: Ruijin Hospital
Interventions
clozapine gene therapy
Updated 1 time since 2025 Last updated: Jul 24, 2025 Started: Aug 1, 2025 Primary completion: Dec 30, 2025 Completion: Dec 30, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
Listed as NCT07085195, this EARLY_PHASE1 trial focuses on Clozapine and Gene Therapy and remains actively recruiting participants. Sponsored by Ruijin Hospital, it has been updated 1 time since 2025, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
1 version recorded Not Yet Recruiting — EARLY_PHASE1
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Ruijin Hospital
Data source: Ruijin Hospital
For direct contact, visit the study record on ClinicalTrials.gov .